Literature DB >> 9572090

Cognitive function and dementia in six areas of England and Wales: the distribution of MMSE and prevalence of GMS organicity level in the MRC CFA Study. The Medical Research Council Cognitive Function and Ageing Study (MRC CFAS).

.   

Abstract

BACKGROUND: This two-stage prevalence survey involved geographically delimited areas, four urban (Liverpool, Newcastle, Nottingham and Oxford) and two rural (Cambridgeshire and Gwynedd), including institutions.
METHODS: Stratified random population samples of people in their 65th year and above, from Family Health Service Authorities were studied. The sample was stratified (65-74 years and > or = 75) to provide equal numbers. In Liverpool equal numbers in 5 year age groups were taken. After an initial screening interview, approximately 20% were selected on the basis of age, AGECAT organicity confidence level and MMSE score to proceed to a detailed assessment interview from which the full AGECAT organicity confidence level could be derived.
RESULTS: Major influences on MMSE were confirmed as age, sex, social class and educational level. Estimates of prevalence of AGECAT O3 and above for each centre and the entire sample according to age are given, based on 1991 Census population structure, and suggest that around half a million (543,400) people in England and Wales would be defined as case level by this method. The five centres employing the same methodology showed no heterogeneity in prevalence.
CONCLUSIONS: Prevalence of cognitive impairment and dementia appear not to vary widely across the centres examined in this study, which provides stable estimates by age and sex for AGECAT O3 and above, and norms for MMSE. Using these estimates as an indication of the size of the population affected, around 550,000 individuals in England and Wales would be expected to be suffering from dementia of mild or greater severity.

Entities:  

Mesh:

Year:  1998        PMID: 9572090     DOI: 10.1017/s0033291797006272

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  70 in total

1.  Drugs for Alzheimer's disease.

Authors:  J T O'Brien; C G Ballard
Journal:  BMJ       Date:  2001-07-21

2.  Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments.

Authors:  P McNamee; A Vanoli; D Hutchings; I McKeith; J Bond
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

3.  Cognitive function in the Caerphilly study: associations with age social class, education and mood.

Authors:  J E Gallacher; P C Elwood; C Hopkinson; P M Rabbitt; B T Stollery; P M Sweetnam; C Brayne; F A Huppert
Journal:  Eur J Epidemiol       Date:  1999-02       Impact factor: 8.082

4.  Improving healthcare for people with dementia in England: good progress but more to do.

Authors:  Nick Black; Josie Dixon; Stefanie Tan; Martin Knapp
Journal:  J R Soc Med       Date:  2015-10-02       Impact factor: 5.344

Review 5.  Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 1.

Authors:  Richard Mayeux; Christiane Reitz; Adam M Brickman; Mary N Haan; Jennifer J Manly; M Maria Glymour; Christopher C Weiss; Kristine Yaffe; Laura Middleton; Hugh C Hendrie; Lauren H Warren; Kathleen M Hayden; Kathleen A Welsh-Bohmer; John C S Breitner; John C Morris
Journal:  Alzheimers Dement       Date:  2011-01       Impact factor: 21.566

6.  Using the Folstein Mini Mental State Exam (MMSE) to explore methodological issues in cognitive aging research.

Authors:  Todd Monroe; Michael Carter
Journal:  Eur J Ageing       Date:  2012-06-15

7.  Profile of disability in elderly people: estimates from a longitudinal population study.

Authors:  D Melzer; B McWilliams; C Brayne; T Johnson; J Bond
Journal:  BMJ       Date:  1999-04-24

Review 8.  Stroke, dementia, and drug delivery.

Authors:  G A Ford; C A Bryant; A A Mangoni; S H D Jackson
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

9.  Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study.

Authors:  Fiona E Matthews; Carol Brayne; James Lowe; Ian McKeith; Stephen B Wharton; Paul Ince
Journal:  PLoS Med       Date:  2009-11-10       Impact factor: 11.069

10.  Lewy bodies and neuronal loss in subcortical areas and disability in non-demented older people: a population based neuropathological cohort study.

Authors:  M Byford; C Brayne; I McKeith; M Chatfield; Pg Ince; Fe Matthews
Journal:  BMC Geriatr       Date:  2009-06-15       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.